AbCellera Biologics Inc.
ABCL
$3.73
$0.092.47%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.96M | 17.08M | 4.24M | 5.05M | 6.51M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.96M | 17.08M | 4.24M | 5.05M | 6.51M |
| Cost of Revenue | 55.03M | 39.21M | 42.50M | 46.08M | 40.97M |
| Gross Profit | -46.07M | -22.13M | -38.26M | -41.03M | -34.46M |
| SG&A Expenses | 24.96M | 21.99M | 19.07M | 19.16M | 22.28M |
| Depreciation & Amortization | 5.25M | 5.47M | 5.33M | -19.44M | 36.92M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 85.23M | 66.67M | 66.90M | 45.81M | 100.17M |
| Operating Income | -76.28M | -49.59M | -62.66M | -40.76M | -93.66M |
| Income Before Tax | -68.77M | -36.34M | -52.98M | -46.83M | -62.63M |
| Income Tax Expenses | -11.65M | -1.62M | -7.36M | -12.62M | -11.53M |
| Earnings from Continuing Operations | -57.12M | -34.73M | -45.62M | -34.21M | -51.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.12M | -34.73M | -45.62M | -34.21M | -51.11M |
| EBIT | -76.28M | -49.59M | -62.66M | -40.76M | -93.66M |
| EBITDA | -71.03M | -44.11M | -57.33M | -26.04M | -56.74M |
| EPS Basic | -0.19 | -0.12 | -0.15 | -0.12 | -0.17 |
| Normalized Basic EPS | -0.14 | -0.08 | -0.11 | -0.06 | -0.17 |
| EPS Diluted | -0.19 | -0.12 | -0.15 | -0.12 | -0.17 |
| Normalized Diluted EPS | -0.14 | -0.08 | -0.11 | -0.06 | -0.17 |
| Average Basic Shares Outstanding | 298.88M | 298.51M | 297.69M | 295.52M | 294.85M |
| Average Diluted Shares Outstanding | 298.88M | 298.51M | 297.69M | 295.52M | 294.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |